Skip to content

Author

Cheng-long Huang

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC

Background Aminopeptidase N (CD13) has been reported to be a prognostic factor in non-small cell lung cancer (NSCLC). DFP-14323 (INN: ubenimex) is a CD13 inhibitor and a low-toxicity, non-specific immunomodulator approved in Japan for the maintenance treatment of adult acute non-lymphocytic leukemia. Objectives This st...

Hiroshige Yoshioka, Masahide Mori, N. Katakami et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.